Donepezil

RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs

Retrieved on: 
Thursday, November 9, 2023

PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024.

Key Points: 
  • PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024.
  • There are two forms of the disease; wet AMD and dry AMD.
  • ADI estimates there are over 10 million new cases of dementia each year worldwide, implying one new case every 3.2 seconds.
  • The Company’s novel approach includes the use of high-resolution retinal imaging and pharmacogenetic mapping to be combined with the promise of these investigational drugs.

Public advisory - Donepezil 10 mg tablets: One lot recalled due to possible oversized tablets

Retrieved on: 
Saturday, November 25, 2023

Pro Doc Limitée is recalling one lot of Donepezil (donepezil hydrochloride) 10 mg tablets due to the possibility that some bottles might contain oversized tablets.

Key Points: 
  • Pro Doc Limitée is recalling one lot of Donepezil (donepezil hydrochloride) 10 mg tablets due to the possibility that some bottles might contain oversized tablets.
  • Health Canada is warning patients and their caregivers that taking an oversized tablet could receive up to three times the intended dose (i.e.
  • Donepezil is a prescription drug used for the symptomatic treatment of mild, moderate, and severe Alzheimer's disease.
  • If your pill bottle of Donepezil 10 mg tablets contains larger-than-normal tablets, or if you are unsure, return it to your pharmacy.

Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia

Retrieved on: 
Thursday, August 10, 2023

Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; “Lotus”), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.

Key Points: 
  • Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; “Lotus”), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.
  • The companies expect to file for regulatory approval in some Asian markets later this year.
  • Under the terms of the agreement, Lotus will have exclusive rights to commercialize ADLARITY® in the applicable territory and will be responsible for the regulatory approval process.
  • According to IQVIA data, the market size of donepezil in the 10 markets in the territory is USD 185 Million.

Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates

Retrieved on: 
Thursday, May 11, 2023

BOTHELL, Wash., May 11, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the first quarter ended March 31, 2023, and reviewed recent pipeline and business updates.

Key Points: 
  • The Company has selected the 40 mg dose for further development and potential regulatory approval for mild to moderate AD.
  • Net cash used in operations was $26.2 million for the quarter ended March 31, 2023, compared with $16.6 million for the quarter ended March 31, 2022.
  • R&D expenses were $21.3 million for the quarter ended March 31, 2023, compared with $14.5 million for the quarter ended March 31, 2022.
  • G&A expenses were $8.5 million for the quarter ended March 31, 2023, compared with $8.9 million for the quarter ended March 31, 2022.

CSE Bulletin: New Listing - Alpha Cognition Inc. (ACOG, ACOG.WT)

Retrieved on: 
Friday, April 28, 2023

Toronto, Ontario--(Newsfile Corp. - Le 28 avril/April 2023) - The common shares and warrants of Alpha Cognition Inc. have been approved for listing on the CSE.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - Le 28 avril/April 2023) - The common shares and warrants of Alpha Cognition Inc. have been approved for listing on the CSE.
  • Listing and disclosure documents will be available at www.thecse.com on the trading date.
  • Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.
  • Les actions ordinaires et les bons de souscription d'Alpha Cognition Inc. ont été approuvés pour inscription à la CSE.

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Retrieved on: 
Tuesday, April 25, 2023

BOTHELL, Wash., April 25, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the presentation of new data from its small molecule programs enhancing the HGF/MET neurotrophic system. The data were presented in oral and poster presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting taking place from April 22-27, 2023, in person in Boston, Mass. and virtually.

Key Points: 
  • The data were presented in oral and poster presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting taking place from April 22-27, 2023, in person in Boston, Mass.
  • “These and other data presented at this year’s AAN Annual Meeting further support other previously reported post hoc findings from ACT-AD that showed improvements in plasma biomarkers and measures of cognition.
  • Additionally, we reported new data that further elucidate the interaction between fosgonimeton and AChEIs.
  • The information presented in this press release is solely the responsibility of Athira and does not necessarily represent the official views of the National Institutes of Health.

Global Alzheimer's Disease Therapeutics Market Research Report 2023: A $7.16 Billion Market by 2028 - 150+ Assets in Various Development Phases - Epidemiology & Pipeline Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 28, 2023

The increasing prevalence of Alzheimer's disease is driving the growth of the global Alzheimer's disease therapeutics market.

Key Points: 
  • The increasing prevalence of Alzheimer's disease is driving the growth of the global Alzheimer's disease therapeutics market.
  • The Alzheimer's disease therapeutics market portfolio contains a total of 151+ assets in various development phases.
  • The Alzheimer's disease therapeutics market has been witnessing considerable growth, which is attributed to the increasing prevalence of Alzheimer's Disease worldwide.
  • The global Alzheimer's disease therapeutics market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating Alzheimer's Disease.

The Worldwide Alzheimer's Drugs Industry is Expected to Reach $7.48 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 24, 2023

The Global Alzheimer's Drugs Market is forecasted to be around USD 7.48 Billion by 2027, according to the publisher.

Key Points: 
  • The Global Alzheimer's Drugs Market is forecasted to be around USD 7.48 Billion by 2027, according to the publisher.
  • Instead, the disease is caused by genetic, lifestyle, and environmental components that influence the brain over time.
  • According to the World Health Organization (WHO), Alzheimer's disease contributes to 60%-70% of dementia cases.
  • As per this research report, Globally Alzheimer's Drugs Market was valued at US$ 5.16 Billion in 2022.

Insights on the Alzheimer's Drugs Global Market to 2027 - Hospital Sector will Capture more Revenue in Upcoming Years

Retrieved on: 
Wednesday, January 25, 2023

The Global Alzheimer's Drugs Market is forecasted to be around USD 7.48 Billion by 2027, according to the publisher.

Key Points: 
  • The Global Alzheimer's Drugs Market is forecasted to be around USD 7.48 Billion by 2027, according to the publisher.
  • Based on Drug class, the Alzheimer's disease drug market is segmented into; Donepezil, Galantamine, Rivastigmine, Memantine, and Others.
  • The hospital segment dominated the market share, owing to the growth in the hospitalization of the older population and Alzheimer's patients.
  • Based on region, the Alzheimer's disease market is divided into; North America, Europe, Asia-Pacific, and the Rest of the World.

Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies

Retrieved on: 
Tuesday, November 29, 2022

TOKYO, Nov 29, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced that its application for a partial change to label for Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies (DLB) that was discovered and developed in-house, regarding dosage and administration for the treatment of DLB in Japan, has been approved today.

Key Points: 
  • TOKYO, Nov 29, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced that its application for a partial change to label for Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies (DLB) that was discovered and developed in-house, regarding dosage and administration for the treatment of DLB in Japan, has been approved today.
  • (Please refer to "Notes to Editors" on the link below for details of the changes)
    This partial change to label is based on the results of a reexamination for the indication of "suppression of progression of dementia symptoms in dementia with Lewy bodies" of this drug, which was categorized as Category 2.
  • After receiving approval for the partial change in dosage and administration for DLB, Eisai will continue to place the highest priority on the provision of proper use and safety information for this drug, and will make continued contributions to address the diversified needs of, and increase the benefits provided to people living with DLB and their families.
  • For more information visit www.eisai.com/news/2022/news202282.html.